Virobay is a clinical-stage pharmaceutical company based in Menlo Park, CA, developing small-molecule cathepsin (cysteine) protease inhibitors. Its platform is being developed to treat neuropathic pain, autoimmune diseases and fibrosis, and the pipeline also includes dermatology programs. The company's lead product candidate is VBY-036, targeted for the treatment of neuropathic pain. Virobay and its proprietary cathepsin platform were spun out from Celera Genomics. The company said it will use proceeds from the financing to advance its clinical programs, specifically the clinical development of VBY-036. Virobay has raised an aggregate of $18 million in two tranches of the Series B financing.

Total raised

$8M

Funding rounds

1

Latest round

Series B

Latest activity

Jul 2014